Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
J Cardiovasc Pharmacol Ther ; 26(3): 217-224, 2021 May.
Article in English | MEDLINE | ID: covidwho-1127659

ABSTRACT

The SARS-CoV-2 virus has resulted in over 88 million cases worldwide of COVID-19 as of January 2021. The heart is one of the most commonly affected organs in COVID-19, but the nature and extent of the cardiac pathology has remained controversial. It has been shown that patients infected with SARS-CoV-2 can sustain type 1 myocardial infarction in the absence of significant atherosclerotic coronary artery disease. However, many patients present with small elevations of troponin enzymes of unclear etiology which correlate with overall COVID-19 disease outcome. Early autopsy reports indicated variable levels of typical lymphocytic myocarditis, while radiology reports have indicated that myocarditis can be a persistent problem after recovery from acute illness, raising concern about participation in college athletics. In this communication, we review the literature to date regarding the gross and microscopic findings of COVID-19 cardiac involvement, present the findings from over 40 cases from our academic medical center, and propose mechanisms by which patients develop small elevations in troponin. .


Subject(s)
COVID-19/pathology , Heart/physiopathology , Angiotensin-Converting Enzyme 2/metabolism , Comorbidity , Diagnostic Imaging , Humans , Inflammation Mediators/metabolism , Myocardial Infarction/pathology , Myocarditis/pathology , SARS-CoV-2 , Troponin/biosynthesis
2.
J Cardiovasc Pharmacol Ther ; 26(3): 203-216, 2021 05.
Article in English | MEDLINE | ID: covidwho-983818

ABSTRACT

Although COVID-19 is viewed primarily as a respiratory disease, cardiovascular risk factors and disease are prevalent among infected patients and are associated with worse outcomes. In addition, among multiple extra-pulmonary manifestations, there has been an increasing recognition of specific cardiovascular complications of COVID-19. Despite this, in the initial stages of the pandemic there was evidence of a reduction in patients presenting to acute cardiovascular services. In this masterclass review, with the aid of 2 exemplar cases, we will focus on the important therapeutic implications of COVID-19 for interventional cardiologists. We summarize the existing evidence base regarding the varied cardiovascular presentations seen in COVID-19 positive patients and the prognostic importance and potential mechanisms of acute myocardial injury in this setting. Importantly, through the use of a systematic review of the literature, we focus our discussion on the observed higher rates of coronary thrombus burden in patients with COVID-19 and acute coronary syndromes.


Subject(s)
COVID-19/physiopathology , Coronary Thrombosis , Fibrinolytic Agents/administration & dosage , Humans , Inflammation Mediators/metabolism , Pandemics , Percutaneous Coronary Intervention/methods , SARS-CoV-2 , ST Elevation Myocardial Infarction/pathology , Thrombosis/pathology , Troponin/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL